Avalo Therapeutics Appoints Ron Philip to Board of Directors
Avalo Therapeutics named Ron Philip to its board, adding more than 30 years of biopharmaceutical leadership as the clinical-stage company advances IL-1β pathway therapeutics toward commercialization.
Avalo Therapeutics appointed Ron Philip to its board of directors, the clinical-stage biotechnology company announced June 23 [1]. Philip brings more than 30 years of biopharmaceutical leadership, with experience in commercial and strategic execution, including guiding multiple companies through product launches and billion-dollar exits [1].
Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases [1]. The company trades on Nasdaq under ticker .
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.